Novartis (NVS) is close to a deal to purchase Avidity Biosciences (RNA) for more than $70 per share, Michelle Davis of Bloomberg reports, citing a person familiar with the matter. The deal could be announced as early as Sunday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- NVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Trump Trade: Trump administration prepares new probe into pharma prices
- Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer
- Novartis announces Cosentyx met primary endpoint in Phase III REPLENISH trial